New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

Thu, 06/28/2012 - 12:24am
Boehringer Ingelheim

Ingelheim, Germany, 28 June 2012 - Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly fewer hypoglycaemic events and resulted in relative weight loss of 2.7 kg compared to glimepiride. 1

The publication reports on a two-year, randomised, double-blind study in 1,552 patients evaluating the efficacy of linagliptin compared to glimepiride as measured by a reduction in HbA1c from baseline in patients uncontrolled on metformin alone. 1



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.